Navigation Links
Immucor to Announce Fiscal 2010 Guidance on Monday, June 1, 2009

NORCROSS, Ga., May 19 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that it will release its fiscal 2010 guidance on Monday, June 1, 2009 after the market close. The Company will host a conference call on Tuesday, June 2, 2009 at 8:30 a.m. (Eastern time) to discuss the results.

Investors are invited to participate in this conference call by dialing 1-888-324-7567 (Passcode: BLUD). Investors can also access the call via Webcast through the "About Us - Investor Information" section at A copy of the press release will be available at the same Web address.

For those unable to listen to the live broadcast, a replay of the conference call will be available shortly after its completion and will be archived on Immucor's website for approximately 60 days. Additionally, investors may access a replay of the call for one week beginning at noon on June 2nd by dialing 1-800-964-0911 (Passcode: 2583).

About Immucor

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit our website at

SOURCE Immucor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Immucor to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
2. Immucor Receives Subpoena From Department of Justice
3. Immucor Announces Fiscal Third Quarter Results
4. Immucor Announces New Vice President, Operations
5. Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance
6. Immucor Closes BioArray Acquisition
7. Immucor Schedules Fiscal 2009 Guidance Call
8. Immucor Responding to FDA Warning Letter
9. Immucor Announces Record Fiscal Third Quarter Results
10. Immucor Schedules Third Quarter Earnings Release and Conference Call
11. Immucor, Inc. Adds Director to Board
Post Your Comments:
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: